Futura Medical plc announced that it has entered into a ground breaking licensing agreement with Haleon plc for the rights to exclusively commercialise the Company's innovative topical, gel-based Erectile Dysfunction treatment MED3000, in the USA. Commercial Highlights: Futura to receive: an initial upfront payment of $4 million; royalty payments on all sales of MED3000 by Haleon; and potential commercial and performance-driven sales milestone payments totaling between $5 million and $45 million payable over the course of several years; Haleon is responsible for the future launch and ongoing regulatory, development, marketing, and commercialization of MED3000 in the USA. Upon launch, MED3000 will represent the first OTC topical gel indicated for the treatment of ED Haleon Licensing Agreement Under the terms of the agreement Haleon will commercialise MED3000 as the first and only clinically proven gel treatment for ED, available without the need for a doctor's prescription in the USA, the biggest consumer healthcare market globally.

Haleon will be responsible for all investment and activities related to the launch and marketing of the product in the USA. Futura will provide ongoing technical support for OTC product development and commercialisation opportunities. The prevalence of ED disrupts the lives of at least 1 in 5 men globally with around 22 million men suffering ED in the USA, making the US market the largest ED market in the world.

The majority of ED sufferers in the USA do not currently treat their condition. MED3000 will meet the needs of many of these ED sufferers by providing a safe, effective and fast-acting treatment that can be purchased without a prescription. MED3000 has previously been approved as the first pan-European clinically proven topical treatment for ED available OTC and is now available in Belgium and the UK.